Genelux Corporation (GNLX)

Market Cap	131.45M +43.8%
Revenue (ttm)	8,000
Net Income	-33.58M
EPS	-0.85
Shares Out	44.41M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	116,792
Open	2.910
Previous Close	2.880
Day's Range	2.850 - 3.028
52-Week Range	2.290 - 8.535
Beta	0.55
Analysts	Strong Buy
Price Target	17.50 (+494.23%)
Earnings Date	May 7, 2026

About GNLX

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec (olvimulogene nanivacirepvec), a proprietary modified strain of the vaccinia virus indicated for the treatment of ovarian cancer. It also offers CHOICE, a technology and discovery and development platform; and developed an extensive library of isolated and engineered oncolytic VACV immunotherapeutic product...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jan 26, 2023
• Employees: 26
• Stock Exchange: NASDAQ
• Ticker Symbol: GNLX
• Website: https://www.genelux.com

Financial Performance

In 2025, Genelux's revenue was $8,000, a change of 0.00% compared to the previous year's $8,000. Losses were -$32.15 million, 7.62% more than in 2024.

Analyst Summary

According to 6 analysts, the average rating for GNLX stock is "Strong Buy." The 12-month stock price target is $17.5, which is an increase of 494.23% from the latest price.

Price Target

$17.5

(494.23% upside)

Analyst Consensus: Strong Buy